United Therapeutics settles patent litigation with Watson Labs; licenses rights to generic Tyvaso
As part of a patent settlement, United Therapeutics Corp. licensed Watson Laboratories Inc. rights to market a generic version of Tyvaso inhalation solution (treprostinil; marketed for the treatment of pulmonary arterial hypertension) beginning on January 1, 2026. Watson's generics business is part of Teva as Allergan PLC divested the business in July 2015.
- Generic Drugs
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com